Anthera Pharmaceuticals, Inc.
ANTH
ANTH was delisted on the 27th of June, 2018.
40 hedge funds and large institutions have $4.81M invested in Anthera Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 20 reducing their positions, and 26 closing their positions.
33% less funds holding
Funds holding: 60 → 40 (-20)
40% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 20
56% less capital invested
Capital invested by funds: $11.1M → $4.81M (-$6.25M)
77% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$836K |
| 2 |
Millennium Management
New York
|
+$323K |
| 3 |
ECM
Element Capital Management
New York
|
+$96.7K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$83.4K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$1.36M |
| 2 |
BlackRock
New York
|
-$664K |
| 3 |
State Street
Boston,
Massachusetts
|
-$287K |
| 4 |
SCM
Sio Capital Management
New York
|
-$142K |
| 5 |
SG Americas Securities
New York
|
-$98K |
ANTH Hedge Fund Activity: Q2 2017 in Review
40 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q2 2017, worth a combined $4.81M — down 56% from $11.1M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ANTH and 6 opened new positions — a net loss of 20 holders — while 20 trimmed existing stakes and 12 added.
The largest buyer was Sabby Management, adding an estimated $836K. The largest seller was Franklin Resources, exiting entirely with an estimated $1.36M sold.
- 40 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q2 2017, down from 60 in Q1 2017.
- Funds reported $4.81M of Anthera Pharmaceuticals, Inc. stock for Q2 2017, down 56% quarter-over-quarter.
- 6 funds opened new Anthera Pharmaceuticals, Inc. positions in Q2 2017 and 26 closed out, a net change of -20 holders.
- The largest Anthera Pharmaceuticals, Inc. buyer in Q2 2017 was Sabby Management, an estimated $836K added.
- The largest Anthera Pharmaceuticals, Inc. seller in Q2 2017 was Franklin Resources, an estimated $1.36M sold.
Based on aggregated 13F filings for Q2 2017.